Morphine and morphine-glucuronide concentrations in plasma and CSF during long-term administration of oral morphine.
Concentrations of morphine, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) were measured by h.p.l.c. in plasma and cerebrospinal fluid (CSF) samples from 16 patients with cancer receiving oral (controlled-release) morphine. There was a close correlation between plasma and CSF morphine concentrations (r = 0.94, P = 0.0001) and both correlated with drug dosage (r = 0.61, P = 0.013 and r = 0.74, P = 0.0001, respectively). M3G and M6G in plasma and CSF were correlated (r = 0.81 and r = 0.82, both P = 0.0001). No relationship was apparent between M plus M6G concentrations in the CSF and pain scores.
van Dongen
R T
RT
Institute for Anesthesiology, University Hospital Nijmegen, The Netherlands.
Crul
B J
BJ
Koopman-Kimenai
P M
PM
Vree
T B
TB
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002851:Chromatography, High Pressure Liquid; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D009020:Morphine / Q000008:administration & dosage / Q000097:blood* / Q000134:cerebrospinal fluid / Q000627:therapeutic use; D009022:Morphine Derivatives / Q000097:blood* / Q000134:cerebrospinal fluid; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D010146:Pain / Q000188:drug therapy*; D010147:Pain Measurement
D003692:Delayed-Action Preparations; D009022:Morphine Derivatives; C035349:morphine-6-glucuronide; D009020:Morphine; C018108:morphine-3-glucuronide